Blog
RSS FeedPosted by Michael Wonder on 17 Sep 2024
Rozanolixizumab for the treatment of patients with generalised antibody positive myasthenia gravis
13 September 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 17 Sep 2024
Rucaparib camsylate for the maintenance treatment of patients with relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (final guidance)
17 September 2024 - NICE has published final evidence-based recommendations on the use of rucaparib camsylate (Rubraca) for the maintenance ...
Posted by Michael Wonder on 12 Sep 2024
Empagliflozin for the treatment of adolescents with type 2 diabetes mellitus
12 September 2024 - NICE is unable to make a recommendation on the use of empagliflozin (Jardiance) in the NHS for ...
Posted by Michael Wonder on 12 Sep 2024
Futibatinib for previously treated patients with advanced cholangiocarcinoma with FGFR2 fusion or rearrangement
11 September 2024 - NICE has published final evidence-based recommendations on futibatinib (Lytgobi) for previously treated advanced cholangiocarcinoma with FGFR2 ...
Posted by Michael Wonder on 12 Sep 2024
Faricimab for the treatment of patients with visual impairment caused by macular oedema after retinal vein occlusion
11 September 2024 - NICE has published final evidence-based recommendations on the use of faricimab (Vabysmo) for the treatment of ...
Posted by Michael Wonder on 11 Sep 2024
Exagamglogene autotemcel for the treatment of patients 12 years of age and older with transfusion-dependent beta-thalassaemia
11 September 2024 - NICE has published final evidence-based recommendations on the use of exagamglogene autotemcel (Casgevy) for the treatment ...
Posted by Michael Wonder on 11 Sep 2024
Evinacumab for the treatment of patients 12 years of age and older with homozygous familial hypercholesterolaemia
11 September 2024 - NICE has published final evidence-based recommendations on the use of evinacumab (Evkeeza) for the treatment of ...
Posted by Michael Wonder on 10 Sep 2024
Pembrolizumab for adjuvant treatment of patients with resected non-small-cell lung cancer
29 August 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 09 Sep 2024
Zolbetuximab in combination with chemotherapy for the first-line treatment of adults with unresectable advanced, claudin 18.2 positive HER2 negative gastric or gastro-oesophageal junction adenocarcinoma
9 September 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 06 Sep 2024
Fedratinib dihydrochloride monohydrate for the treatment of patients with disease-related splenomegaly or symptoms in myelofibrosis
6 September 2024 - The Department of Health and Social Care has asked NICE to review its guidance on the ...
Posted by Michael Wonder on 06 Sep 2024
Pegzilarginase for the treatment of patients with arginase-1 deficiency
6 September 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 05 Sep 2024
Adults with von Hippel-Lindau disease to benefit from new treatment
5 September 2024 - NICE has recommended belzutifan for some adults with von Hippel-Lindau disease, in final draft guidance, which could ...
Posted by Michael Wonder on 04 Sep 2024
Zanubrutinib for the treatment of patients with marginal zone lymphoma after anti-CD20-based treatment
4 September 2024 - NICE has published final evidence-based recommendations on the use of zanubrutinib (Brukinsa) for the treatment of ...
Posted by Michael Wonder on 04 Sep 2024
Iptacopan hydrochloride for the treatment of patients with paroxysmal nocturnal haemoglobinuria
4 September 2024 - NICE has published final evidence-based recommendations on the use of iptacopan hydrochloride (Fabhalta) for the treatment ...
Posted by Michael Wonder on 04 Sep 2024
Vibegron for the treatment of patients with symptoms of overactive bladder syndrome
4 September 2024 - NICE has published final evidence-based recommendations on the use of vibegron (Obgemsa) for the treatment of ...